ASSOCIATION OF NONSWITCHED MEMORY B-CELL (MBC) LEVELS WITH OZANIMOD (OZA) EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (CD): RESULTS FROM THE PHASE 2 STEPSTONE STUDY

Sarah Harris  ¹     Brian G. Feagan  ²     Steve Hanauer  ³     Severine Vermeire  ⁴     Subrata Ghosh  ⁵     Jim Yan  ⁶     Chun Wu  ⁶     Yanhua Hu  ⁶     Rachel Maddux  ⁶     Douglas C. Wolf  ⁷     Geert D’Haens  ^8    
1 Bristol Myers Squibb, Princeton, United States
² Robarts Research Institute, Western University, London, Ontario, Canada
³ Northwestern University Feinberg School of Medicine, Chicago, United States
⁴ University of Leuven, Leuven, Belgium
⁵ APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland
⁶ Laboratory Corporation of America, Durham, United States
⁷ Center for Crohn’s Disease & Ulcerative Colitis, Atlanta Gastroenterology Associates, Atlanta, United States
⁸ Inflammatory Bowel Disease Center, Amsterdam University Medical Center, Amsterdam, Netherlands

Topic
IBD

Session
Sequential therapies in IBD: Raising the bar

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)